A role of sFlt-1 in oxidative stress and apoptosis in human and mouse pre-eclamptic trophoblasts

Biology of Reproduction

Volumn 93, Issue 3, 2015, Pages

  Jiang, Ziyan ^a   Zou, Yanfen ^b   Ge, Zhiping ^a   Zuo, Qing ^a   Huang, Shi Yun ^a   Sun, Lizhou ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Mice; Oxidative stress; Pre eclampsia; sFlt 1

Indexed keywords

MALONALDEHYDE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RECOMBINANT ENZYME; SOLUBLE FMS LIKE TYROSINE KINASE 1; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; FLT1 PROTEIN, HUMAN; FLT1 PROTEIN, MOUSE; VASCULOTROPIN RECEPTOR 1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ELECTRON MICROSCOPY; ELEVATED BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MATERNAL AGE; MEAN ARTERIAL PRESSURE; MITOCHONDRION SWELLING; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLACENTA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; TROPHOBLAST; UPREGULATION; ANIMAL; DRUG EFFECTS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; FEMALE; HUMANS; MALONDIALDEHYDE; MICE; MICE, INBRED ICR; MITOCHONDRIAL SWELLING; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; SUPEROXIDE DISMUTASE; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84943238969     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.114.126227     Document Type: Article

References (33)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785-799.
2. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066-1074.
3. de Oliveira LG, Karumanchi A, Sass N. Preeclampsia: oxidative stress, inflammation and endothelial dysfunction [in Portuguese]. Rev Bras Ginecol Obstet 2010; 32(12):609-616.
4. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006; 8(3):1-20.
5. Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech 2012; 5(1):9-18.
6. Sharma D, Singh A, Trivedi SS, Bhattacharjee J. Intergenotypic variation of nitric oxide and inflammatory markers in preeclampsia: a pilot study in a North Indian population. Hum Immunol 2011; 72(5):436-439.
7. Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, Wallukat G, Dechend R, Lamarca B. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension 2013; 62(6):1068-1073.
8. Zhou X, Zhang GY, Wang J, Lu SL, Cao J, Sun LZ. A novel bridge between oxidative stress and immunity: the interaction between hydrogen peroxide and human leukocyte antigen G in placental trophoblasts during preeclampsia. Am J Obstet Gynecol 2012; 206(5):447.e7-16.
9. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 2004; 145:4835-4837.
10. Liu LY, Yang T, Ji J, Wen Q, Morgan AA, Jin B, Chen G, Lyell DJ, Stevenson DK, Ling XB, Butte AJ. Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia. BMC Med 2013; 11(1):236.
11. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89:770-775.
12. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50:1702-1703.
13. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010; 5:e13263.
14. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 2009; 28:95-108.
15. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
16. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38:718-722.
17. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940-950.
18. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95(9):884-891.
19. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
20. Jiang ZY, Guo YY, Ren HB, Zou YF, Fan MS, Lv Y, Han P, De W, Sun LZ. Tumor necrosis factor (TNF)-α upregulates progesterone receptor-A by activating the NF-κB signaling pathway in human decidua after labor onset. Placenta 2012; 33(1):1-7.
21. Ziyan J, Huaibin R, Xiaotian M, Guangtong S, Xiaoqing C, Zijiang D, Ziyue J, We D, Lizhou S. Regulation of progesterone receptor A and B expression in human preterm, term, and postterm placental villi. Acta Obstet Gynecol Scand 2010; 89:705-711.
22. Krysiak O, Bretschneider A, Zhong E, Webb J, Hopp H, Verlohren S, Fuhr N, Lanowska M, Nonnenmacher A, Vetter R, Jankowski J, Paul M, et al. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates down-regulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ Res 2005; 97(12):1253-1261.
23. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006; 91(6):2424-2427.
24. Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109(6):1368-1374.
25. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21(1):9-23.
26. Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens 2012; 30:2173-2181.
27. Govender L, Mackraj I, Gathiram P, Moodley J. The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia. Cardiovasc J Afr 2012; 23:153-159.
28. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50:137-142.
29. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009; 22:564-568.
30. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fmslike tyrosine kinase-1 expression. Hypertension 2007; 50(6):1142-1147.
31. Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. Int J Biochem Cell Biol 2010; 42(10):1634-1650.
32. Murata M, Fukushima K, Takao T, Seki H, Takeda S, Wake N. Oxidative stress produced by xanthine oxidase induces apoptosis in human extravillous trophoblast cells. J Reprod 2013; 59(1):7-13.
33. Cali U, Cavkaytar S, Sirvan L, Danisman N. Placental apoptosis in preeclampsia, intrauterine growth retardation, and HELLP syndrome: an immunohistochemical study with caspase-3 and bcl-2. Clin Exp Obstet Gynecol 2013; 40(1):45-48.